Stock DNA
Pharmaceuticals & Biotechnology
SAR 10,080 Million (Small Cap)
26.00
NA
0.00%
-0.10
27.19%
6.10
Revenue and Profits:
Net Sales:
396 Million
(Quarterly Results - Jun 2025)
Net Profit:
132 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.54%
0%
-9.54%
6 Months
-11.18%
0%
-11.18%
1 Year
-12.64%
0%
-12.64%
2 Years
28.75%
0%
28.75%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Jamjoom Pharmaceuticals Factory Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.44%
EBIT Growth (5y)
16.61%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.09
Sales to Capital Employed (avg)
0.85
Tax Ratio
5.60%
Dividend Payout Ratio
60.08%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
26.93%
ROE (avg)
21.80%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
6.71
EV to EBIT
25.22
EV to EBITDA
23.07
EV to Capital Employed
7.41
EV to Sales
7.70
PEG Ratio
1.12
Dividend Yield
NA
ROCE (Latest)
29.37%
ROE (Latest)
26.14%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
396.20
345.70
14.61%
Operating Profit (PBDIT) excl Other Income
144.00
114.00
26.32%
Interest
0.30
0.20
50.00%
Exceptional Items
0.00
-0.10
100.00%
Consolidate Net Profit
132.00
107.00
23.36%
Operating Profit Margin (Excl OI)
336.70%
301.60%
3.51%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 14.61% vs 15.85% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 23.36% vs 23.99% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,318.50
1,100.80
19.78%
Operating Profit (PBDIT) excl Other Income
418.00
343.10
21.83%
Interest
0.70
0.60
16.67%
Exceptional Items
-10.30
-5.90
-74.58%
Consolidate Net Profit
356.50
292.40
21.92%
Operating Profit Margin (Excl OI)
288.60%
287.50%
0.11%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 19.78% vs 20.08% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 21.92% vs 70.69% in Dec 2023
About Jamjoom Pharmaceuticals Factory Co. 
Jamjoom Pharmaceuticals Factory Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






